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Background: Nephropathy is the main problem of diabetes and can be classified into several 
phases according to the presence of albuminuria. Adenosine monophosphate-activated 
protein kinase (AMPK) operates as a sensor of energy charge.
Objectives: The aim of our study was to evaluate the reno-protective properties of AMPK 
signaling pathway against streptozotocin (STZ)-induced nephropathy in the rat.
Materials and Methods: Forty male Wistar rats were randomly distributed into four groups. 
Group 1 was normal rats (N group); group 2 was diabetic rats (D group); group 3 received 
diabetic rats + metformin (DM group), and group 4 received giabetic rats + metformin + 
dorsomorphin (DMD group). Serum albumin, uric acid, total protein and creatinine for 
estimation of renal injury were measured. Finally, the histological study was evaluated. 
Results: Reduction of body weight, albumin and total protein in the diabetic rat was reversed 
by metformin administration. Our results showed that serum uric acid and creatinine were 
significantly increased in diabetic rats and decreased after treatment with metformin in 
diabetic rats. AMPK improved the histopathology and morphological changes in STZ-
induced diabetic rats. Administration of dorsomorphin (AMPK inhibitor) with metformin 
can reverse the beneficial effects of AMPK.
Conclusions: AMPK signaling pathway ameliorates diabetic nephropathy by modifications 
of serum albumin, uric acid, total protein, creatinine and attenuation of kidney damage.
ABSTRACT
Implication for health policy/practice/research/medical education:
In this experimental study, we found that activation of  AMPK via metformin can protect nephropathy against STZ-induced 
diabetes in models of  rats. The main mechanism of  AMPK in renoprotective effects was increased serum albumin and total 
protein levels and decreased serum uric acid and creatinine levels after treatment with metformin in diabetic rats.
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1. Background 
Nephropathy is the main complication of  diabetes 
mellitus and show one of  the main challenges for 
modern nephrology as the most cause of  chronic kidney 
disease, accounting for common about 30%-40% of  new 
cases of  diabetes (1). Diabetic nephropathy, also called 
diabetic kidney disease, can be classified into several 
phases conforming to the presence of  albuminuria and 
the degree of  chronic kidney disease (2). In the kidneys, 
glucose by binding to proteins, lead to the production 
of  advanced glycosylation end products (AGEs). AGE 
contribute to renal damage by stimulation and release of 
proinflammatory cytokines and expression of  growth 
factors in the development of  diabetic nephropathy 
(3). A diabetes preventive role for medications such as 
metformin has been suggested (4). Metformin is an anti-
diabetic medicine used for in the treatment of  diabetes 
mellitus (type II), and it is used as the treatment for 
other metabolic diseases (5,6). The mechanism of  action 
of  metformin is suggested to be through activation of 
adenosine monophosphate-activated protein kinase 
(AMPK) (7,8). The main objective of  metformin seems 
to be the mitochondrial respiratory chain complex Ι 
leading to activation of  AMPK (9). AMPK operates 
as a sensor of  energy charge (10) that is activated with 
elevation of  AMP (11) concomitant with decreased 
cellular ATP levels (12). 
2. Objectives
The present study aimed to evaluate the nephroprotective 
effects of  AMPK signaling pathway in rodent models of 
streptozotocin-induced diabetic nephropathy.
3. Materials and Methods
3.1. Materials
Materials are rats (prepared by the faculty of  medical 
school, Tehran University of  Medical Sciences), 
streptozotocin (Sigma-Aldrich, USA), metformin and 
dorsomorphin dihydrochloride (Tocris Bioscience, USA)
3.2. Methods
3.2.1. Animals
Forty male Wistar rats weighing 210±10 g, in the 
department of  pharmacology, school of  medicine, 
Tehran Medical Science University, were used in this 
study. The animals were in a room with a temperature of 
22 ± 2°C and 12-h light/12-h dark cycle and free access 
to food and water. The rats were weighed and were kept 
for 20 to 24 hours are hungry and randomly allocated 
into four groups as follows:
Group I (N group); normal rats 
Group II (D group); diabetic rats 
Group III (DM group); diabetic rats + metformin 
Group IV (DMD group); diabetic rats + metformin + 
dorsomorphin. 
Metformin activates AMPK can be administered orally 
(300 mg/kg) in the body and dorsomorphin (0.2 mg/kg) 
daily intraperitoneal injection (IP) injection was used as an 
inhibitor of  the activity of  AMPK. Diabetes was induced 
in rats of  groups II, III and IV were injected with single 
intraperitoneal of  65 mg/kg of  streptozotocin (STZ). 
STZ was freshly dissolved in 0.05 M citrate buffer. Blood 
glucose levels were measured after 48 hours with blood 
from the tail vein and animals whose blood glucose with 
400 mg/dL were considered as diabetic rats were used in 
the study. In the groups which received dorsomorphin 
and metformin, drug used 72 hours after induction of 
diabetes, and as each day until 6 weeks after induction of 
diabetes. Evaluation of  the effect of  serum parameters 
amd histopatologic study were done on 6 weeks after 
induction of  diabetes. Body weight of  each animal was 
determined at the initiation and end of  the study.
3.2.2. Serum parameters
At the end of  the treatment period, rats were anesthetized 
with pentobarbital intended (70 mg/kg, IP), blood 
samples were collected into tubes without anticoagulant 
and centrifuged at 3000 rpm for 10 minutes to sepatation 
of  serum, and the serum was stored at -70°C untile assay. 
Serum samples were used for measurement of  albumin, 
uric acid, total protein and creatinine by enzymatic 
colorimetric methods according to the standard protocol 
of  manufacturer’s instructions (13). 
3.2.3. Histological study
For renal morphological studies, in 45th after induced 
nephropathy, the right kidney was isolated and fixed in 
buffered formalin, dehydrated in histoligical paraffin. 
Renal sample was sectioned (5 µm) and stained with 
hematoxylin and eosin (13). 
3.3. Ethical issues
The research followed the tenets of  the Declaration 
of  Helsinki. This project was approved by Ethics 
Committee of  Tehran University of  Medical. Prior to 
the experiment, the protocols were confirmed to be 
in accor dance with the guidelines of  Animal Ethics 
Committee of  Tehran University of  Medical Sciences. 
3.4. Statistical analysis
One-way analysis of  variance (ANOVA) analysis 
followed by Tukey post hoc test was used for evaluation. 
All data are presented as means ± standard deviation 
(SD). Results were considered significant when P value 
<0.05.
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4. Results 
4.1. Body weight
Table 1 demonstrates the effect of  metformin on 
body weight. Diabetic rats (D group) show exhibited 
significant weight loss period compared to the control 
rats. At the end of  6 weeks treatment, the body weight 
of  animals treated with metformin (300 mg/kg) was 
significantly improved compared with the STZ-diabetic 
group (P < 0.05). However, treatment with metformin 
and dorsomorphin cannot be attenuated the body weight 
in the DMD group.
4.2. Serum albumin assessment
Administration of  STZ led to significant decrease in serum 
albumin levels in the D group as compared to the normal 
group (N group) throughout 6 weeks after induction of 
diabetes by STZ in rats (P < 0.001). Furthermore, at the 
end of  6 weeks treatment, diabetic animals treated with 
300 mg/kg metformin demonstrated attenuating in the 
serum albumin levels (P < 0.05). In diabetic rats treated 
with metformin and dorsomorphin, a decrease in the 
serum albumin levels was detected (Figure 1).
4.3. Serum uric acid measurement
The diabetic animals showed a significant increase in 
the level of  uric acid compare to the normal group 
(P < 0.001). After treatment with metformin in group 
III (DM group), serum uric acid decreased significantly 
(P < 0.001). Also, the diabetic rats treated with metformin 
and dorsomorphin (DMD group) showed a significant 
reduction of  serum uric acid levels as compared to the 
group II (P < 0.05, Figure 2). 
4.4. Assessment the level of  total proteins
After 6 weeks, STZ-diabetic rats (group II) showed a 
significant decrease in the levels of  total protein when 
compared with normal group (group 1) (P < 0.001). 
Animal’s treatment with 300 mg/kg metformin (group 
III) showed a significant increase in the levels of  total 
proteins compared with their D group (P < 0.01). 
Interestingly, in group DMD (group IV), concomitant 
metformin and dorsomorphin administration to inhibit 
AMPK signaling pathway, showed a significant increase 
in level of  serum total proteins compared with diabetic 
control (group 2) after 6 weeks (P < 0.05, Figure 3).
4.5. Assessment the level of  serum creatinine
STZ-diabetic rats (group II) showed a significant 
increase in the serum levels of  creatinine (P < 0.001). 
Furthermore, the levels of  creatinine significantly 
decreased in the serum of  DM group (group III) 
compared to diabetic rats (P < 0.01, Figure 4). Also, this 
parameter was not significant in diabetic rats treated with 
metformin and dorsomorphin (DMD group).
4.6. Histological study
Figure 5 shows the histological study of  renal tissues 
of  rats from the non-diabetic group and experimental 
Table 1. Assessment of  body weight
N D DM DMD
Body weight (g, 6 weeks) 274.7±5.08 162.5±3.39*** 171.2±4.19# 166.1±3.48
*** P < 0.001 compared to normal group; # P < 0.05 compared to diabetic group.
N: Normal group (Non-diabetic group), D: Diabetic group, DM: Diabetic + Metformin group and DMD: Diabetic + Metformin + 
Dorsomorphin group.
Group
Figure 1. Assessment of  Albumin. *** P < 0.001 compared to 
Normal group, # P < 0.05 compared to Diabetic group.
N: Normal group (non-diabetic group), D: Diabetic group, DM: 
Diabetic + Metformin group and DMD: Diabetic + Metformin + 
Dorsomorphin group.
Figure 2. Assessment of  Uric acid. *** P < 0.001 compared to 
normal group, # P < 0.05 and ### P < 0.001 compared to diabetic 
group.
N: Normal group (Non-diabetic group), D: Diabetic group, DM: 
Diabetic + Metformin group and DMD: Diabetic + Metformin + 
Dorsomorphin group.
Group
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groups. In the non-diabetic group, renal glomeruli 
seemed to be normal. In the diabetic group, increased 
tubular damage, tubulointerstitial injuries and glomerular 
damage. Metformin significantly improved the tubular 
damage in diabetic renal damage. However, dorsomorphin 
treatment with metformin reversed the beneficial effects 
of  metformin on renal histopathological in diabetic rats.
5. Discussion
In this study, we evaluated the reno-protective effects of 
AMPK signaling pathway in the diabetic nephropathy 
induced by STZ in rat. Treatment with metformin in 
diabetic rat attenuated the body weight in compared to 
untreated diabetic rats (P < 0.05). However, the results 
in this study showed that administration metformin 
with dorsomorphin did not improve the body weight 
in diabetic rats. We showed that metformin, an AMPK 
activator, significantly increased the albumin (P < 0.05) 
and total protein (P < 0.01) and also, decreased the levels 
of  creatinine (P < 0.01) and uric acid (P < 0.001) in the 
serum of  diabetic rats. In addition, co-treatment of 
dorsomorphin with metformin decreased the positive 
effects of  metformin on serum albumin and creatinine. 
Furthermore, the evaluation of  histopathological studies 
demonstrated that activate AMPK signaling pathway 
attenuate the kidney tissue damage that is caused by 
STZ-diabetes. 
STZ-induced type 1 diabetic rats are associated with 
severe decrease of  body weight caused by hyperglycemia, 
loss of  tissue proteins (14), muscular tissue and adipose 
tissue (15). Additionally, the increase in the levels of 
serum uric acid and creatinine (16) and the decrease 
in the levels of  serum albumin and total protein (17) 
have been associated with diabetic kidney disease. STZ 
induced diabetes (type 1) has been determined as a useful 
experimental model for study of  diabetes because STZ 
causes selective destruction of  the β-cell in pancreatic 
islets (18, 19). It has been shown that dorsomorphin 
(AMPK inhibitor) can reverse the beneficial effects of 
AMPK (20). Metformin is currently the drug of  choice 
for the management of  diabetes. It improves plasma 
levels of  glucagon-like peptide 1 (GLP-1), peripheral 
and liver sensitivity to insulin, decreases hepatic glucose 
production, and causes weight reduction (21). A recent 
study demonstrated that metformin stimulates the 
adenosine monophosphate protein kinase signaling 
pathway (22). Lee et al reported that phosphorylation 
of  AMPK signaling levels is diminished in the diabetes-
induced renal hypertrophy (23). In addition, Kim et 
al suggested that AMPK activation in renal tissues by 
metformin attenuated, loss of  podocyte in nephropathy 
Figure 3. Assessment of  Total Protein. 
*** P < 0.001 compared to normal group, # P < 0.05 and ## P < 0.01 
compared to diabetic group.
N: Normal group (Non-diabetic group), D: Diabetic group, DM: 
Diabetic + Metformin group and DMD: Diabetic + Metformin + 
Dorsomorphin group. 
Figure 4. Assessment of  serum creatinine.
*** P < 0.001 compared to Normal group, ## P < 0.01 to diabetic 
group.
N: Normal group (Non-diabetic group), D: Diabetic group, DM: 
Diabetic + Metformin group and DMD: Diabetic + Metformin + 
Dorsomorphin group.
Figure 5. Assessment of  histological study. A: Normal group 
(Non-diabetic group), B: Diabetic group, C: Diabetic + Metformin 
group and D: Diabetic + Metformin + Dorsomorphin group.
Group
Group
A
C D
B
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8. Hasanvand A, Amini-khoei H, Hadian M-R, Abdollahi 
A, Tavangar SM, Dehpour AR, et al. Anti-inflammatory 
effect of  AMPK signaling pathway in rat model of  diabetic 
neuropathy. Inflammopharmacology. 2016;24(5):207-219. 
doi: 10.1007/s10787-016-0275-2.
9. He X, Tu SM, Lee M, Yeung SJ. Thiazolidinediones and 
metformin associated with improved survival of  diabetic 
prostate cancer patients. Ann Oncol. 2011;22(12):2640-5. 
doi: 10.1093/annonc/mdr020.
10. Steinberg GR, Kemp BE. AMPK in Health and 
Disease. Physiol Rev. 2009;89(3):1025-78. doi: 10.1152/
physrev.00011.2008.
11. Hardie DG. AMP-activated/SNF1 protein kinases: 
conserved guardians of  cellular energy. Nat Rev Mol Cell 
Biol. 2007;8(10):774-85. doi:10.1038/nrm2249.
12. Hardie DG, Hawley SA. AMP-activated protein kinase: 
the energy charge hypothesis revisited. Bioessays. 
2001;23(12):1112-9. doi: 10.1002/bies.10009.
13. Hasanvand A, Abbaszadeh A, Darabi S, Nazari A, 
Gholami M, Kharazmkia A. Evaluation of  selenium 
on kidney function following ischemic injury in rats; 
protective effects and antioxidant activity. J Renal Inj Prev. 
2016;24;6(2):93-98. doi: 10.15171/jrip.2017.18. 
14. Zafar M, Naqvi SN. Effects of  STZ-Induced diabetes on 
the relative weights of  kidney, liver and pancreas in Albino 
rats: a comparative study. Int J Morphol. 2010;28(1):135-
42. doi: 10.4067/S0717-95022010000100019.
15. Gomes RM, de Paulo LF, Bonato Panizzon CPN, Neves 
CQ, Cordeiro BC, Zanoni JN, et al. Anti-diabetic effects of 
the ethyl-acetate fraction of  Trichilia catigua in streptozo-
tocin-induced type 1 diabetic rats. Cell Physiol Biochem. 
2017;29;42(3):1087-97. doi: 10.1159/000478761.
16. Yuan YL, Guo CR, Cui LL, Ruan SX, Zhang CF, Ji D, et al. 
Timosaponin B-II ameliorates diabetic nephropathy via 
of  diabetes (24). Furthermore, it has been shown that 
treatment with metformin significantly decreased 
albuminuria in diabetic patients (25) and serum creatinine 
in STZ-nicotinamide-induced diabetic nephropathy in 
rats (26) and also serum uric acid in gout patients (27). 
Renal cell damage induced by cisplatin-induced tubular 
cell apoptosis and acute kidney injury attenuated by 
activation of  AMPK with metformin (28). In another 
study, in mouse renal fibroblasts activation of  AMPK 
pathway using metformin diminished the renal interstitial 
fibrosis in chronic kidney disease (29). Zhang et al 
showed that the expression of  phosphorylated AMPK 
via metformin attenuated metabolic renal function in 
mice (30).
6. Conclusions
The data of  this study suggested that AMPK signaling 
pathway has a protective effect on kidney in the diabetic 
nephropathy induced by STZ in the rat. Our results 
suggested that AMPK showed protective effect by 
attenuating complications of  diabetic nephropathy 
through preventing a rise in uric acid and creatinine 
levels, and reduced albumin and total protein levels. 
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